New Bedrocan production facility manufactures in accordance with GMP

| |
0
71

As of November 2017, the new Dutch Bedrocan production facility officially manufactures in accordance with Good Manufacturing Practice (GMP). This guarantees that Bedrocan meets international pharmaceutical quality and safety requirements.

Bedrocan is the world’s most experienced producer of legal medicinal cannabis,  headquartered in Netherlands. It is the second time that a Bedrocan production site has been made compliant with the GMP requirements for an active pharmaceutical ingredient. Earlier this year, the manufacturer of standardised medicinal cannabis acquired a GMP certificate for the existing Dutch production site. This made Bedrocan the first manufacturer in the world where the entire production process – including cultivation – complies with the international requirements imposed on the production of pharmaceutical raw materials and end products.

On 15 September 2017, the new Bedrocan production site harvested the first batch of standardised medicinal cannabis and handed it over to the Office of Medicinal Cannabis. The new site, outfitted with state-of-the-art finishings and fittings, has a surface area of 10,000 m2, half of which is in use at the moment. With this significant increase in production capacity, Bedrocan meets the growing demand for standardised medicinal cannabis of pharmaceutical quality.

SOURCE: bedrocan
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.
Isaltis Banner